利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

42 条记录 (耗时 0.029 秒)

    Methods for treating ocular conditions with cyclic lipid contraining microparticles
    21.
    发明申请
    Methods for treating ocular conditions with cyclic lipid contraining microparticles 审中-公开
    用抑制微粒的环状脂质治疗眼部病症的方法

    公开(公告)号：US20060182781A1

    公开(公告)日：2006-08-17

    申请号：US11368845

    申请日：2006-03-06

    申请人： Patrick Hughes ,  Joan-En Chang-Lin ,  Devin Welty

    发明人： Patrick Hughes ,  Joan-En Chang-Lin ,  Devin Welty

    IPC分类号： A61F2/00

    CPC分类号： A61F9/00781 ,  A61F2210/0004 ,  A61K9/0051 ,  A61K9/1647 ,  A61K31/00

    摘要： Biocompatible microparticles include a ophthalmically active cyclic lipid component and a biodegradable polymer that is effective, when placed into the subconjunctival space, in facilitating release of the cyclic lipid component into the anterior and posterior segments of an eye for an extended period of time. The cyclic lipid component can be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the cyclic lipid component can be encapsulated by the polymeric component. The present microparticles include oil-in-oil emulsified microparticles. The subconjunctivally administered microparticles can be used to treat or to reduce at least one symptom of an ocular condition, such as glaucoma or age related macular degeneration.

    摘要翻译： 生物相容的微粒包括眼科活性的环状脂质组分和可生物降解的聚合物，当放置在结膜下空间中时，有利于将脂质组分释放到眼睛的前部和后部段中延长的时间。 环状脂质组分可与可生物降解的聚合物基质相结合，例如两种可生物降解聚合物的基质。 或者，环状脂质组分可以被聚合物组分包封。 本发明的微粒包括油包水乳化微粒。 结膜下施用的微粒可用于治疗或减少眼部疾病如青光眼或年龄相关性黄斑变性的至少一种症状。

    Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
    23.
    发明授权
    Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates 有权
    使用具有增强的前清除率的α-2肾上腺素能受体化合物进行眼部治疗

    公开(公告)号：US07931909B2

    公开(公告)日：2011-04-26

    申请号：US11416929

    申请日：2006-05-02

    申请人： Patrick M. Hughes ,  James A. Burke ,  Joan-En Chang-Lin

    发明人： Patrick M. Hughes ,  James A. Burke ,  Joan-En Chang-Lin

    IPC分类号： A61K9/00

    CPC分类号： A61K9/0051 ,  A61K9/0048 ,  A61K9/1647

    摘要： Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component which includes an alpha 2 adrenergic receptor agonist that is cleared from the anterior segment of an individual's eye to which the material is administered. The alpha 2 adrenergic receptor agonist may have a vitreal half-life greater than about three hours. The present materials are effective in treating an ocular condition(s) that affect the anterior segment of an eye, or the anterior and posterior segment of the eye. The materials are suitable for intravitreal or periocular administration and can provide prolonged drug delivery and therapeutic benefits to patients to which the materials have been administered. The alpha 2 adrenergic receptor agonists can be provided in liquid-containing formulations and/or bioerodible and/or non-bioerodible polymeric implants and microparticles. Methods of making and using the present materials are also described.

    摘要翻译： 眼科治疗材料，例如含液组合物和聚合物药物递送系统，包括治疗成分，其包括α2肾上腺素能受体激动剂，其从施用该物质的个体眼睛的前段清除。 α2肾上腺素能受体激动剂可具有大于约3小时的玻璃体半衰期。 本发明的材料可有效治疗影响眼前段或眼部前段和后段的眼睛状况。 这些材料适用于玻璃体内或眼周内给药，并且可以为已经施用材料的患者提供延长的药物递送和治疗益处。 α2肾上腺素能受体激动剂可以在含液制剂和/或生物可侵蚀和/或非生物可侵蚀的聚合物植入物和微粒中提供。 还描述了制备和使用本发明材料的方法。